116 related articles for article (PubMed ID: 15940252)
21. Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC).
Kim DW; Chung HK; Park KC; Hwang JH; Jo YS; Chung J; Kalvakolanu DV; Resta N; Shong M
Mol Endocrinol; 2007 Dec; 21(12):3039-49. PubMed ID: 17761947
[TBL] [Abstract][Full Text] [Related]
22. Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation.
Hwang JH; Kim DW; Suh JM; Kim H; Song JH; Hwang ES; Park KC; Chung HK; Kim JM; Lee TH; Yu DY; Shong M
Mol Endocrinol; 2003 Jun; 17(6):1155-66. PubMed ID: 12637586
[TBL] [Abstract][Full Text] [Related]
23. Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC.
Kim YR; Byun HS; Won M; Park KA; Kim JM; Choi BL; Lee H; Hong JH; Park J; Seok JH; Kim DW; Shong M; Park SK; Hur GM
BMC Cancer; 2008 May; 8():144. PubMed ID: 18498667
[TBL] [Abstract][Full Text] [Related]
24. SH2B1beta adaptor is a key enhancer of RET tyrosine kinase signaling.
Donatello S; Fiorino A; Degl'Innocenti D; Alberti L; Miranda C; Gorla L; Bongarzone I; Rizzetti MG; Pierotti MA; Borrello MG
Oncogene; 2007 Oct; 26(45):6546-59. PubMed ID: 17471236
[TBL] [Abstract][Full Text] [Related]
25. The Shc family protein adaptor, Rai, negatively regulates T cell antigen receptor signaling by inhibiting ZAP-70 recruitment and activation.
Ferro M; Savino MT; Ortensi B; Finetti F; Genovese L; Masi G; Ulivieri C; Benati D; Pelicci G; Baldari CT
PLoS One; 2011; 6(12):e29899. PubMed ID: 22242145
[TBL] [Abstract][Full Text] [Related]
26. Targeting RET to induce medullary thyroid cancer cell apoptosis: an antagonistic interplay between PI3K/Akt and p38MAPK/caspase-8 pathways.
Mazumdar M; Adhikary A; Chakraborty S; Mukherjee S; Manna A; Saha S; Mohanty S; Dutta A; Bhattacharjee P; Ray P; Chattopadhyay S; Banerjee S; Chakraborty J; Ray AK; Sa G; Das T
Apoptosis; 2013 May; 18(5):589-604. PubMed ID: 23329180
[TBL] [Abstract][Full Text] [Related]
27. RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.
Croyle M; Akeno N; Knauf JA; Fabbro D; Chen X; Baumgartner JE; Lane HA; Fagin JA
Cancer Res; 2008 Jun; 68(11):4183-91. PubMed ID: 18519677
[TBL] [Abstract][Full Text] [Related]
28. AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.
Couto JP; Almeida A; Daly L; Sobrinho-Simões M; Bromberg JF; Soares P
PLoS One; 2012; 7(10):e46869. PubMed ID: 23056499
[TBL] [Abstract][Full Text] [Related]
29. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
[TBL] [Abstract][Full Text] [Related]
30. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
31. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines.
Miyake I; Hakomori Y; Shinohara A; Gamou T; Saito M; Iwamatsu A; Sakai R
Oncogene; 2002 Aug; 21(38):5823-34. PubMed ID: 12185581
[TBL] [Abstract][Full Text] [Related]
32. Comparative expression profiles of Trk receptors and Shc-related phosphotyrosine adapters during retinal development: potential roles of N-Shc/ShcC in brain-derived neurotrophic factor signal transduction and modulation.
Nakazawa T; Nakano I; Sato M; Nakamura T; Tamai M; Mori N
J Neurosci Res; 2002 Jun; 68(6):668-80. PubMed ID: 12111828
[TBL] [Abstract][Full Text] [Related]
33. Differential membrane compartmentalization of Ret by PTB-adaptor engagement.
Lundgren TK; Luebke M; Stenqvist A; Ernfors P
FEBS J; 2008 May; 275(9):2055-66. PubMed ID: 18355321
[TBL] [Abstract][Full Text] [Related]
34. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM
Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368
[TBL] [Abstract][Full Text] [Related]
35. Genomic organization of the Shc-related phosphotyrosine adapters and characterization of the full-length Sck/ShcB: specific association of p68-Sck/ShcB with pp135.
Kojima T; Yoshikawa Y; Takada S; Sato M; Nakamura T; Takahashi N; Copeland NG; Gilbert DJ; Jenkins NA; Mori N
Biochem Biophys Res Commun; 2001 Jun; 284(4):1039-47. PubMed ID: 11409899
[TBL] [Abstract][Full Text] [Related]
36. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
[TBL] [Abstract][Full Text] [Related]
37. Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels.
Wang J; Knauf JA; Basu S; Puxeddu E; Kuroda H; Santoro M; Fusco A; Fagin JA
Mol Endocrinol; 2003 Jul; 17(7):1425-36. PubMed ID: 12690093
[TBL] [Abstract][Full Text] [Related]
38. RET/PTC oncoproteins: molecular targets of new drugs.
Lanzi C; Cassinelli G; Cuccuru G; Zanchi C; Laccabue D; Zunino F
Tumori; 2003; 89(5):520-2. PubMed ID: 14870776
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic Met receptor induces cell-cycle progression in Xenopus oocytes independent of direct Grb2 and Shc binding or Mos synthesis, but requires phosphatidylinositol 3-kinase and Raf signaling.
Mood K; Saucier C; Ishimura A; Bong YS; Lee HS; Park M; Daar IO
J Cell Physiol; 2006 Apr; 207(1):271-85. PubMed ID: 16331688
[TBL] [Abstract][Full Text] [Related]
40. Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells.
Castellone MD; Celetti A; Guarino V; Cirafici AM; Basolo F; Giannini R; Medico E; Kruhoffer M; Orntoft TF; Curcio F; Fusco A; Melillo RM; Santoro M
Oncogene; 2004 Mar; 23(12):2188-96. PubMed ID: 14981541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
